 intens sequenti chemotherapi mitoxantron continu infus etoposid cytarabin acut myelogen leukemia intens sequenti chemotherapi mitoxantron day continu infus day cytarabin continu infus day patient year acut myelogen leukemia aml forti patient refractori aml nonrespons therapi earli first relaps multipl relaps late first relaps percent patient confid interv CI complet remiss CR CI refractori patient CI late first relaps patient twenty-nin percent patient CI CI therapy-rel toxic median durat aplasia day nonhematolog who toxic sepsi patient mucos diarrhea skin rash hyperbilirubinemia postinduct therapi CR patient second cours regimen mainten chemotherapi underw autolog bone marrow transplant bmt allogen bmt median follow-up month complet remitt month achiev CR patient bmt median surviv month CI surviv month median disease-fre surviv month CI CR patient disease-fre month twenty-six percent CI evalu patient transplant invers CR durat patient year signific differ disease-fre surviv patient postinduct chemotherapi bmt chemotherapi regimen effici first-lin therapi young patient aml